The potential of CD۱۹ molecule in targeted immunotherapy in leukemia

Background: Immunotherapy is one of the most encouraging areas of therapeutic progress in acute leukemia. In the last ۱۰ years, chimeric antigen receptor T cell therapy (CART) has been successful in treating leukemia. The turning point for these patients has been the development of anti-CD۱۹ T-cell chimeric antigen receptor. In the past decades, blood malignancies were treated with chemotherapy, radiation therapy and stem cell transplantation. CAR is an immunotherapy method in which T cells are treated with an anti-CD۱۹ antibody fragment. In this article, the aim is to investigate the potential of CD۱۹ molecule in targeted immunotherapy in leukemia.Materials and Methods: The collection of articles related to the potential of CD۱۹ molecule in leukemia immunotherapy from PubMed, Google Scholar, and NCBI databases with keywords CD۱۹, immunotherapy, leukemia searched. Finally ۷۰ articles related to the topic of review and analyses were found.Results: The level of expression of CD۱۹ in ۸۰% of ALL, in B cell lymphomas is ۸۸% and in B cells is ۱۰۰% normal to high. Treatment of refractory B-cell lymphoma with an improved version of CD۱۹-BBz CAR-T without causing neurotoxicity or severe CRS is a drug therapy with anti-CD۱۹ CAR-T cells.Canclusion: This article has investigated the effects of CAR-T cell treatments on the clinical treatment of the main subgroups of leukemia. According to the recent advances in the treatment of blood malignancies with the method of CAR-T cells targeting CD۱۹, we can witness the complete treatment of leukemia patients with immunotherapy.

کلیدواژه ها:

CAR-T ، CD۱۹ ، immunotherapy ، leukemia